
Orakl Oncology SA raises €3m to advance tumour modelling
French precision oncology start-up Orakl Oncology has raised €3m in a seed financing round led by Speedinvest with additional investment from...

microRNA could offer a safe target in atherosclerosis
The researcher demonstrateded that targeting of miR-206-3p with an experimental compound safely reversed the onset of atherosclerosis in a...

Quotient Therapeutics kicks-off with US$50m financing
Flagship has confírmed to invest $50m in Quotient Therapeutics to advance development of a platform, licenced from Wellcome Sanger Institue...

Agomab Therapeutics NV raises US$100m in Series C financing
The closed financing round was led by Fidelity Management & Research Company. New investors EQT Life Sciences, Canaan and Dawn Biopharma/KKR, as...

SpliceBio has made up a US $216m alliance with Spark Therapeutics
Under a globally exclusive licence option agreement with Roche AG, SpliceBio secures an upfront payment, opt-in and milestone payments up to $216m...

Crucible Therapeutics spins out with £5m
Crucible Therapeutics Ltd., the newly launched spinout company from the University of Sheffield, secured the investment of £5m from Northern...

Alfasigma SpA set to take over Galapagos programme
Under the planned agreement, Alfasigma SpA will pay €50m upfront, milestones totaling €120m and mid-single to mid-double digit royalties on European...